In a finding that could reshape how scientists think about one of the world’s most persistent parasitic infections, researchers in Japan have uncovered evidence that the gut microbiome may actively help Entamoeba histolytica—the parasite responsible for amoebiasis—survive unnoticed in the intestines of asymptomatic carriers. The study, published in the journal Gut Pathogens, combines shotgun metagenomic profiling of a human cohort with laboratory experiments showing that a microbiota-derived bile acid can extend parasite survival and reduce its susceptibility to the frontline drug metronidazole.
Entamoeba histolytica is a formidable global health problem. The single-celled parasite infects an estimated tens of millions of people worldwide, causing symptomatic disease ranging from debilitating diarrhea and colitis to life-threatening liver abscesses. Yet a large proportion of infected individuals carry the organism without any symptoms at all, quietly shedding cysts in their stool and sustaining the chain of transmission in their communities. Understanding why some people become silent reservoirs of the parasite has long been a central question in the field, and the new study points to an unexpected accomplice: the trillions of bacteria that inhabit the human gut.
The research team, led by Yasuaki Yanagawa of the AIDS Clinical Center at the National Center for Global Health and Medicine and Koji Watanabe of Tokai University School of Medicine, recruited 36 participants from a prospectively screened outpatient cohort at a sexual health clinic in Tokyo. Each participant provided paired stool and serum samples at the same visit, allowing the researchers to categorize them according to parasite burden. Some participants were negative for the parasite, some tested positive only by quantitative polymerase chain reaction (qPCR), indicating low-level molecular detection, and a third group was cyst-positive, meaning actively shedding the parasite’s transmissible stage. This ordinal classification—running from no infection to molecular detection to active cyst shedding—became the backbone of the analysis.
Rather than simply comparing the gut bacteria of infected and uninfected individuals, the team deployed shotgun metagenomics, a technique that sequences all the genetic material in a stool sample rather than just a single marker gene. This approach provides a detailed census of the microbial community down to the species level. Interestingly, the results suggested that E. histolytica carriage is not accompanied by wholesale disruption of the gut ecosystem. Community-level beta diversity, which measures overall differences in microbial composition between groups, showed no significant separation between the parasite states. Instead, the picture was one of taxon-specific shifts: subtle, targeted changes in particular groups of bacteria rather than a general collapse or rebalancing of the microbiome.
One signal did stand out statistically. Genus richness—the number of distinct bacterial genera present—was higher in the cyst-positive group, with an unadjusted p-value of 0.046. When the researchers applied multivariable modeling to identify individual taxa associated with parasite burden, they found directional but non-significant trends, all with FDR-adjusted q-values above 0.9. In a cohort of 36 people, statistical power is inherently limited, and the authors are careful not to overclaim. Still, the same names kept appearing: genera belonging to the Firmicutes phylum, including Coprococcus, Ruminococcus, and Catenibacterium. These are common residents of the healthy human gut, and their consistent directional association with increasing parasite burden across complementary analytical approaches made them prime candidates for a functional role in supporting colonization.
This is where the study takes its most innovative turn. The team recognized that certain gut bacteria, particularly Firmicutes, are known to convert primary bile acids—molecules produced by the liver and secreted into the intestine—into secondary bile acids through chemical modification. One of the most abundant of these microbially transformed molecules is deoxycholic acid, or DCA. If the microbiome shifts observed in cyst carriers tended to favor bile acid–converting bacteria, the researchers reasoned, then the parasite might be bathing in an intestinal environment chemically altered in its favor. To test this hypothesis, they moved from correlation to causation, bringing the candidate molecule into the laboratory.
In a series of in vitro exposure experiments, the researchers cultured E. histolytica trophozoites—the active, feeding stage of the parasite—in the presence of DCA and, for comparison, cholic acid, a primary bile acid. The results were striking. When nutrients became limiting in the culture medium, a condition mimicking the fluctuating environment of the intestine, 100 micromolar DCA significantly extended parasite survival. Glucose measurements confirmed that nutrient depletion occurred on schedule regardless of bile acid treatment, meaning the survival advantage was not simply a matter of more food being available. Even more consequential for clinical medicine, parasites pretreated with DCA showed reduced susceptibility to metronidazole, the drug that has served as the mainstay of amoebiasis treatment for decades.
To understand how a bile acid could produce these effects, the team turned to transcriptomics—sequencing the messenger RNA of parasites exposed to DCA to see which genes were switched on or off. The response was distinct and highly organized. Among the most dramatically induced genes was an ABC transporter annotated as P-glycoprotein-2, which showed an 8.34-fold increase in expression. ABC transporters are molecular pumps that can expel toxic compounds from cells, and their induction is a classic signature of chemical stress adaptation. Alongside this, DCA exposure upregulated genes involved in lipid remodeling and broader stress-response pathways, painting a picture of a parasite actively reprogramming its membrane composition and cellular defenses in response to the bile acid signal.
KEGG pathway enrichment analysis of the differentially expressed genes reinforced this interpretation, identifying significant enrichment of lipid metabolism and stress-related pathways in DCA-treated parasites. Together, the transcriptomic data support the existence of what the authors describe as a bile acid–driven adaptive program—a coordinated genetic response that equips the parasite to withstand the hostile conditions of the intestinal lumen, from nutrient scarcity to chemical assault. In this framework, DCA is not merely an incidental byproduct of gut bacteria but a kind of environmental signal that E. histolytica may have learned to exploit during its long coevolution with the human host.
The clinical implications of these findings are considerable. Persistent asymptomatic carriage is the engine of amoebiasis transmission, and if microbiome-derived bile acids genuinely promote this state, then the composition of a person’s gut community could influence both their risk of becoming a carrier and their response to treatment. Reduced metronidazole susceptibility in vitro, even if modest, raises the possibility that bile acid exposure at the intestinal mucosa could blunt drug efficacy in vivo, potentially explaining some treatment failures or relapses. It also opens the door to therapeutic strategies that go beyond antibiotics: manipulating the microbiome or its bile acid output could, in principle, strip the parasite of a key survival aid. The authors caution that their human cohort was small and that the microbiome associations, while directionally consistent, did not reach statistical significance after correction for multiple comparisons. The in vitro DCA concentration of 100 micromolar must also be contextualized against actual luminal concentrations in carriers, which the study did not directly measure. Nevertheless, by weaving together human metagenomics, targeted metabolite hypothesis testing, parasite culture, and RNA sequencing, the study offers one of the most mechanistically grounded accounts to date of how the gut ecosystem and E. histolytica might conspire to sustain silent, drug-tolerant infection. The research was supported by Gilead Sciences, JSPS KAKENHI, and the Japan Agency for Medical Research and Development, and was conducted with ethics approval and written informed consent from all participants.
Subject of Research: People and tissue samples
Subject of Research: Biology
Article Title: Gut microbiome–parasite axis linked to persistent Entamoeba histolytica carriage
Article References: Yanagawa, Y., Yoshida, N., Makiuchi, T., Kawashima, A., Uemura, H., Aoki, T., Mizushima, D., Gatanaga, H., & Watanabe, K. (2026). Multi-omics profiling and bile-acid exposure assays implicate a gut microbiome–parasite axis linked to persistent Entamoeba histolytica carriage. Gut Pathogens, 18(1), Article 69. https://doi.org/10.1186/s13099-026-00845-1
Image Credits: AI Generated
DOI: 10.1186/s13099-026-00845-1
Keywords: asymptomatic parasite carriers, gut microbiome and amoebiasis transmission, Gut microbiome–Entamoeba histolytica interaction, implications for global health and parasitic disease control, intestinal microbiota and parasite persistence, metagenomic profiling of gut bacteria, microbiome influence on parasitic infections, microbiome-targeted therapies for amoebiasis, microbiota and drug resistance, microbiota-derived bile acids, parasite survival mechanisms, role of gut bacteria in pathogen survival
Cite Scienmag News
APA MLA Chicago
Morgan Morrow. (September 9, 2026). Gut microbiome–parasite axis linked to persistent Entamoeba histolytica carriage. Scienmag. https://scienmag.com/gut-microbiome-parasite-axis-linked-to-persistent-entamoeba-histolytica-carriage/
Morgan Morrow. “Gut microbiome–parasite axis linked to persistent Entamoeba histolytica carriage.” Scienmag, 9 September 2026, https://scienmag.com/gut-microbiome-parasite-axis-linked-to-persistent-entamoeba-histolytica-carriage/. Accessed 9 September 2026.
Morgan Morrow. “Gut microbiome–parasite axis linked to persistent Entamoeba histolytica carriage.” Scienmag. September 9, 2026. https://scienmag.com/gut-microbiome-parasite-axis-linked-to-persistent-entamoeba-histolytica-carriage/
Copy citation Download RIS
Tags: asymptomatic intestinal carriersasymptomatic parasite carriersgut microbiome and amoebiasis transmissiongut microbiome and antimicrobial resistancegut microbiome and drug resistanceGut microbiome–Entamoeba histolytica interactionimplications for global health and parasitic disease controlintestinal microbiota and parasite persistencemetagenomic profiling of gut bacteriamicrobiome influence on parasite survivalmicrobiome influence on parasitic infectionsmicrobiome-targeted therapies for amoebiasismicrobiota and drug resistancemicrobiota impact on amoebiasis transmissionmicrobiota-derived bile acidsparasite survival mechanismsparasitic infection persistenceparasitic survival mechanisms in the gutrole of gut bacteria in pathogen persistencerole of gut bacteria in pathogen survival
